Sanguine Biosciences

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Sanguine Biosciences sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 3 currently recruiting 4 completed top decile by trial count

Sanguine Biosciences: 11 sponsored US clinical trials, 3 recruiting.

Sanguine Biosciences sponsors 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. The most-studied condition in this pipeline is Huntington; Dementia (Etiology), with 1 trials.

Top-decile sponsor footprint

Sanguine Biosciences ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING

Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

NCT05773196
RECRUITING

A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives

NCT05794217
RECRUITING

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
TERMINATED

Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia

NCT05910853
TERMINATED

Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

NCT05915897
TERMINATED

Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)

NCT05915910
COMPLETED

Biorepository of Biospecimen Samples in Matched Healthy Control Participants and Participants Diagnosed With Diabetic Kidney Disease, Chronic Kidney Disease, or Type 2 Diabetes

NCT05631119
COMPLETED

A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)

NCT05523206
TERMINATED

A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants

NCT06503458
COMPLETED

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
COMPLETED

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

NCT01592552

Therapeutic Areas

Huntington; Dementia (Etiology) 1
Huntington Disease, Late Onset 1
Huntington's Dementia 1
Rare Diseases 1
Allergies 1
Alpha-Gal Syndrome 1
Huntington Disease 1
Amyloidosis 1
Age-related Macular Degeneration 1
Alopecia Areata 1

What is open in the Sanguine Biosciences pipeline

3 recruiting of 11 indexed (27% open); 4 completed (36%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Huntington; Dementia (Etiology) (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sanguine Biosciences: open-pipeline peers nationwide

Peers matched on 11 registered trials and 27% open enrollment, not the therapeutic-area sidebar.

Sanguine Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30% Total trials Recruiting share Sanguine BiosciencesAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeConnecticut Children's Medical CenterCriteriumMinneapolis Heart Institute FoundationNerviano Medical Sciences
Sanguine Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sanguine Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 27% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sanguine Biosciences page

11 registered trials is a research-attention snapshot, not an endorsement of Sanguine Biosciences or any single study.

  • 3 of Sanguine Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Huntington; Dementia (Etiology) is the condition Sanguine Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Huntington; Dementia (Etiology) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sanguine Biosciences pipeline card: 11 registered trials from official public datasets.Report a data error.